|
12/08/24
|
Stable production of anti-sickling adult hemoglobin (HBA T87Q ) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially transformative and durable clinical impact Results from first and only
|
|
|
12/07/24
|
Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up SOMERVILLE, Mass. --(BUSINESS WIRE)--Dec. 7, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with
|
|
|
12/04/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Dec. 4, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company’s common stock following approval by both its Board of Directors
|
|
|
12/04/24
|
Company and CMMI agreed to key terms to be offered to State Medicaid Agencies to support access to LYFGENIA™ gene therapy for sickle cell disease States can opt in to an outcomes-based agreement with bluebird through the Model until February 28, 2025 SOMERVILLE, Mass. --(BUSINESS WIRE)--Dec.
|
|
|
11/14/24
|
- 74 patient starts completed or scheduled to date in 2024 across bluebird’s commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - -
|
|
|
11/06/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Nov. 6, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it partially adjourned its annual meeting of stockholders (“Annual Meeting”) on Wednesday, November 6, 2024 , to allow the Company to solicit additional votes
|
|
|
11/05/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Nov. 5, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia
|
|
|
10/04/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Oct. 4, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement awards of 242,500 restricted stock units (RSUs).
|
|
|
09/27/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep. 27, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”).
|
|
|
09/24/24
|
Actions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep. 24, 2024-- Following a comprehensive review of its operations, bluebird bio, Inc .
|
|
|
09/13/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep. 13, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022 , and for each of the first three quarters of 2022 and 2023.
|
|
|
08/28/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Aug. 28, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference , Wednesday, September 4 , at 12:45
|
|
|
08/23/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Aug. 23, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the “notices”) on August 20, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for
|
|
|
08/14/24
|
- 27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA); anticipate approximately 85 patient starts across the portfolio as LYFGENIA patient starts accelerate in the second half of 2024 - - Second quarter 2024 net revenue of $16.1 million - - Cash runway into Q2 2025 based on
|
|
|
08/12/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Aug. 12, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14 , at 8:00 a.m. ET . To participate in the conference call, please dial +1 (800)
|
|
|
08/02/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Aug. 2, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved an inducement grant of stock options to purchase a total of 38,200 shares of common stock to its controller and vice
|
|
|
07/03/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jul. 3, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial
|
|
|
05/29/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--May 29, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling , has been appointed chief financial officer (CFO), effective June 10, 2024 . Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics
|
|
|
05/09/24
|
- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First quarter 2024 net revenue of $18.6 million - - Management to host conference call
|
|
|
05/06/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--May 6, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9 , at 8:00 a.m. ET . To participate in the conference call, please dial +1 (800) 715-9871 (
|
|
|
05/06/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--May 6, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of
|
|
|
04/26/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 26, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received a notice (the “notice”) on April 24, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the
|
|
|
04/11/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 11, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to twelve newly hired employees with a grant date of April
|
|
|
03/26/24
|
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital - - 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First government outcomes-based agreement for sickle
|
|
|
03/25/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar. 25, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024 , at 8:00 a.m. ET . To access the live conference call via telephone,
|
|
|
03/18/24
|
- Funding expected to extend the Company’s cash runway beyond the next 24 months - - First tranche of $75 million was drawn upon closing; the Company will be eligible to draw an additional $50 million subject to achievement of commercial milestones - SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar.
|
|
|
03/11/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar. 11, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel) with the state of Michigan .
|
|
|
01/08/24
|
Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. lives Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start
|
|
|
01/02/24
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 2, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain , chief executive officer, bluebird bio, will present a corporate update at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 , at 10:30am PT /
|
|